{"product_id":"hd-labs-tirzepatide-60mg-self-mix-copy","title":"BP Tirzepatide 60mg Pen","description":"\u003cp class=\"detail-description\"\u003eRESEARCH USE ONLY!\u003c\/p\u003e\n\u003cp class=\"detail-description\"\u003e \u003c\/p\u003e\n\u003cp\u003eTirzepatide is a peptide studied extensively for its activity across key metabolic and incretin pathways. It functions as a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003edual receptor agonist\u003c\/strong\u003e, acting on:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGLP-1 (glucagon-like peptide-1) receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGIP (glucose-dependent insulinotropic polypeptide) receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThrough this dual mechanism, tirzepatide has been investigated for its effects on insulin secretion, regulation of hepatic glucose production, delayed gastric emptying, and appetite-related signalling.\u003c\/p\u003e\n\u003cp\u003eThis product is supplied as a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003epre-filled injectable pen\u003c\/strong\u003e intended for purchasers who have independently researched the compound and are operating under appropriate professional guidance.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eClinical Trial Evidence (Phase 3)\u003c\/h3\u003e\n\u003cp\u003eTirzepatide has undergone extensive\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ePhase 3 clinical evaluation\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ein large, controlled trials.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIn Phase 3 studies conducted under controlled conditions, tirzepatide demonstrated\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003esubstantial and sustained reductions in body weight\u003c\/strong\u003e, with participants achieving\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eaverage weight reductions of up to approximately 22–23% over 72 weeks\u003c\/strong\u003e, depending on dose and study protocol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePhase 3 programmes also evaluated long-term safety, tolerability, and metabolic outcomes, forming the basis for subsequent regulatory approvals in certain jurisdictions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOutcomes observed in clinical trials are dependent on controlled protocols and\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003edo not guarantee similar results outside of clinical settings\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eHow Tirzepatide Compares\u003c\/h3\u003e\n\u003cp\u003eTirzepatide is often discussed alongside other incretin-based peptides:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003efunctions as a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eGLP-1 receptor agonist only\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003edual agonist\u003c\/strong\u003e, targeting both\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eGLP-1 and GIP receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThis dual activity differentiates tirzepatide from earlier single-pathway GLP-1 compounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eImportant Information\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSupplied as a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003epre-filled injectable pen\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eNo dosing, administration, or medical instructions are provided\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eConsultation with a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003elicensed healthcare provider\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis essential prior to any consideration of use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eResults observed in clinical trials may not reflect real-world outcomes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003cp\u003eThis product is supplied strictly on an\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003einformed purchaser basis\u003c\/strong\u003e. By purchasing, you acknowledge that:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eYou have independently researched this product and its investigational status\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eYou have consulted, or will consult, a qualified healthcare professional\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe seller provides\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eno medical advice, treatment claims, or dosing guidance\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eonus of lawful, safe, and appropriate use rests entirely with the purchaser\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"detail-description\"\u003e \u003c\/p\u003e","brand":"Vitality Lab","offers":[{"title":"Default Title","offer_id":48959560810609,"sku":null,"price":3100.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2457\/3809\/files\/c2002320-91ed-478d-b570-bdaa3a095e3f-BP-Tirz-60mg.jpg?v=1790354147","url":"https:\/\/vitalitylab.co.za\/products\/hd-labs-tirzepatide-60mg-self-mix-copy","provider":"Vitality Lab","version":"1.0","type":"link"}